Results 121 to 130 of about 27,755 (279)

Short‐Term Combined Treatment With Tirzepatide and Metformin for Overweight/Obese Chinese Women With Polycystic Ovary Syndrome: A Prospective, Open‐Label, Randomised Controlled Trial

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims This study aimed to assess the effects of low‐dose tirzepatide combined with metformin (COM) versus metformin (MET) monotherapy in overweight/obese women with polycystic ovary syndrome (PCOS). Materials and Methods Sixty overweight/obese women with PCOS were randomised to the MET group (1000 mg twice daily [BID]) or the COM group (MET ...
Zhuoran Yang, Yuxin Xu, Hu Du, Wenya Liu, Haiyan Chen, Dongfang Liu, Lili Zhang, Cong Wang   +7 more
wiley   +1 more source

Associations Between BioFire FilmArray Gastrointestinal Panel Results and Clinical Outcomes in Infectious Gastroenteritis

Diagnostics
Background/Objectives: Infectious gastroenteritis (IGE) is a major global health concern due to its high morbidity and healthcare burden. The BioFire FilmArray Gastrointestinal Panel (FA-GIP) enables rapid multiplex detection of enteric pathogens ...
Myeong Joo Lee, Ju Yeong Lee, Suhng Wook Kim   +2 more
doaj   +1 more source

Risk of Age‐Related Ocular Diseases in Non‐Diabetic Adults With Obesity Using Glucagon‐Like Peptide 1 Receptor Agonists

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To assess whether glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) are associated with a lower incidence of age‐related ocular diseases in non‐diabetic older adults with overweight or obesity. Materials and Methods We conducted a retrospective, propensity score–matched cohort study using the TriNetX global research network.
Kuo‐En Chen, Po‐Chun Wang, Hui‐An Lin, Sheng‐Feng Lin   +3 more
wiley   +1 more source

Tirzepatide for Obesity in Adults ≥ 65 Years: A Post Hoc Analysis of the SURMOUNT and SUMMIT Clinical Trials

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Tirzepatide is a once‐weekly glucagon‐like peptide‐1 (GLP‐1) and glucose‐dependent insulinotropic polypeptide (GIP) receptor agonist (RA) approved for weight management in adults with obesity. Data on older adults remain limited, however. This study aimed to examine tirzepatide's safety and efficacy in adults aged ≥ 65 years with obesity ...
Nasreen Alfaris, Robert F. Kushner, Jianghao Li, Kevin L. Chen, Mia Fenimore, Boris Calderon, Adam Stefanski   +6 more
wiley   +1 more source

The Gluco- and Liporegulatory and Vasodilatory Effects of Glucose-Dependent Insulinotropic Polypeptide (GIP) Are Abolished by an Antagonist of the Human GIP Receptor

, 2017
A truncated form of human glucose-dependent insulinotropic polypeptide (GIP), GIP(3-30)NH2, was recently identified as an antagonist of the human GIP receptor. This study examined the ability of GIP(3-30)NH2 to antagonize the physiological actions of GIP
Hartmann, Bolette, Sparre-Ulrich, Alexander Hovard, Jens Bülow, Flemming Dela, Lærke Smidt Gasbjerg, Mette Marie Rosenkilde, Bolette Hartmann, Jens Juul Holst, Meena Asmar, Asmar, Meena, Holst, Jens Juul, Dela, Flemming, Bülow, Jens, Rosenkilde, Mette Marie, Simonsen, Lene, Ali Asmar, Alexander Hovard Sparre-Ulrich, Asmar, Ali, Lene Simonsen, Gasbjerg, Lærke Smidt   +19 more
core   +1 more source

Effects of Incretin‐Based Therapies, Diet and Exercise Interventions, and Bariatric Surgery on Fat‐Free Mass in Adults With Overweight or Obesity: A Systematic Review and Meta‐Analysis

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Background Maintaining fat‐free mass (FFM) during weight loss is important to maintain a healthy body composition. This review examined changes in FFM during weight loss induced by diet and exercise interventions, incretin‐based therapies, and bariatric surgery, and assessed whether the relative loss of FFM differs by weight‐loss modality ...
Laura Busk‐Cirera, Ida Ørum Carlsen, Lærke Bruun Madsen, Rasmus Michael Sandsdal, Emma Jensen, Simon Birk Kjær Jensen, Signe Sørensen Torekov   +6 more
wiley   +1 more source

Question 2. Quelles sont les principales modalités de coupes de régénération, en forêts tempérées et boréales, et particulièrement en France métropolitaine ?

, 2023
International audienceLes modalités de renouvellement des peuplements, en particulier les coupes rases, font l’objet de vifs débats. Ce chapitre de l'expertise collective CRREF (Coupes Rases et renouvellement des Peuplement en contexte de changement ...
Landmann, Guy, Gosselin, Marion
core  

Tirzepatide Efficacy and Tolerability According to Early Weight Response: A Post Hoc Analysis of the SURMOUNT‐1 and SURMOUNT‐2 Trials

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Obesity affects over 800 million people globally and is associated with complications including cardiovascular disease and type 2 diabetes (T2D). Early response to weight loss interventions may help optimize achievement of individual treatment goals.
Alexander Kokkinos, Tina Thethi, Clare J. Lee, Lisa M. Neff, Adam Stefanski, Dachuang Cao, Angel Rodriguez, Amy Bartee   +7 more
wiley   +1 more source

Prescribing Trajectories in Type 2 Diabetes in the United States, 2019–2024

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Importance Clinical guidelines for type 2 diabetes (T2D) provide population‐level recommendations, but real‐world treatment patterns evolve dynamically and vary across patients. Understanding longitudinal prescribing trajectories may reveal heterogeneity in care not captured by cross‐sectional analyses.
Tobias S. Lux, Dongkun Lee, Jeff M. Phillips, Julio C. Facelli, Daniel C. Malone, Matthew Wahl, Deepika Reddy, Farrant Sakaguchi, Ramkiran Gouripeddi, Alexander S. Millar, Matthew J. O'Brien, Joshua S. Choi, Jittrapol Sutejitsiri, Kensaku Kawamoto, Polina V. Kukhareva   +14 more
wiley   +1 more source

Antagonistic effects of two novel GIP analogs, (Hyp(3))GIP and (Hyp(3)) GIPLys(16)PAL, on the biological actions of GIP and longer-term effects in diabetic ob/ob mice

, 2007
This study examines the actions of the novel enzyme- resistant, NH2- terminally modified GIP analog ( Hyp(3)) GIP and its fatty acid- derivatized analog ( Hyp(3)) GIPLys(16)PAL.
Hunter, K., Clifford J. Bailey, Flatt, P.R., Finbarr P. M. O'Harte, Brett Greer, Gault, V.A., Harriott, Patrick, Nigel Irwin, Brian D. Green, Peter R. Flatt, Victor A. Gault, Bailey, C.J., Kerry Hunter, Patrick Harriott, O'Harte, F.P.M., Green, Brian, Irwin, N., Greer, Brett   +17 more
core   +1 more source